Cognition Therapeutics Inc. is a drug discovery and development company located in Pittsburgh, Pennsylvania. Founded in 2007, the company uses proprietary biology and chemistry platforms to discover novel drug targets and disease modifying therapies for disorders of the central nervous system.
We are seeking a Neuroscientist at our headquarters in Pittsburgh, PA.
The candidate will be a key contributor to a scientific research team developing cutting edge assay methodology for neurodegenerative protein targets. Responsibilities include evaluation of new targets for neurodegenerative diseases and clinical biomarkers, statistical data analysis, studies of compound mechanism of action, and assay development. Candidate will work with internal team members, contribute to scientific publications and NIH grant applications, and academic collaborators and travel to scientific meetings to present company results.
Ph.D. in Neuroscience or related field plus 5 years experience (industry experience a plus)
Background in neurobiology, pharmacology and biochemistry of target proteins implicated in neurodegeneration
Ability to critically analyze and interpret data, define realistic timelines for studies and meet delivery deadlines
Technical expertise in neurobiological techniques (e.g., primary culture of neurons, imaging techniques, protein biochemistry, design and interpretation of behavioral studies)
Excellent teamwork, communication, and analytical skills
Internal Number: 002
About Cognition Therapeutics
Cognition Therapeutics, Inc. (CogRx) is a
privately held biopharmaceutical company whose disease-relevant screening and novel
chemistry platforms have produced a pipeline of disease modifying small molecule drug
candidates which are being developed to treat Alzheimer’s disease and potentially other
neurocognitive disorders. Cognition’s lead molecule, CT1812, is a proprietary first-in-class,
orally available small molecule that is currently in clinical trials in patients with
mild-to-moderate Alzheimer’s disease. This highly brain penetrant compound targets
the sigma-2 receptor complex, displacing toxic beta amyloid oligomers from their
binding sites on brain cells and clearing them into the cerebrospinal fluid. CT1812 has
been shown in multiple Alzheimer’s disease models to stop memory loss. Additional
information about Cognition may be found online at http://www.cogrx.com.